Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 901–1,000 of 1,001
Bikdeli, B., Khairani, C. D., Barns, B. M., Rosovsky, R. P. G., Jiménez, D., Monréal, M., Sylvester, K. W., Middeldorp, S., Bates, S. M., Krumholz, H. M., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106714 · Cited by 10
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Benzidia, I., Robitaille, C., Abualsaud, A. O., McDonald, L., Lesenko, L., Morin, J., Langleben, D., Kahn, S. R., & Hirsch, A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.07.002 · Cited by 9
Drug Treatment of Venous Thromboembolism in the Elderly
Boey, J. P., & Gallus, A. S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0378-x · Cited by 9
“Table 5 Randomised treatment comparisons in acute VTE: DOACs vs VKA [36, 39, 40, 139]”
BackgroundVoukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232393 · Cited by 10
“Edoxaban dose was 60 mg OD for the majority of the patients [13].”
BackgroundMethodInfluentialFeuring, M., Schulman, S., Eriksson, H., Kakkar, A. K., Schellong, S., Hantel, S., Schueler, E., Kreuzer, J., & Goldhaber, S. Z. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1479-z · Cited by 9
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence
Giustozzi, M., Verso, M., Agnelli, G., & Becattini, C. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1555-4 · Cited by 9
Costa, O. S., Thompson, S. I., Ashton, V., Palladino, M. A., Bunz, T. J., & Coleman, C. I. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00219-w · Cited by 9
Agnelli, G., Hoffmann, U., Hainaut, P., Gaine, S., Ay, C., Coppens, M., Schindewolf, M., Jiménez, D., Brüggenjürgen, B., Lévy, P., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.001 · Cited by 9
Galanaud, J. ‐., Trujillo‐Santos, J., Bikdeli, B., Micco, P. D., Bortoluzzi, C., Bertoletti, L., Pedrajas, J. M., Ballaz, A., Alfonso, J., Monréal, M., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02347-6 · Cited by 9
Self-citationAdherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
Speed, V., Auyeung, V., Patel, J. P., Cooper, D., Miller, S. D., Roberts, L. N., Patel, R., & Arya, R. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12614 · Cited by 9
Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism
Riva, N., & Ageno, W. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.008 · Cited by 9
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade
Charpidou, A. G., Gerotziafas, G., Popat, S., Araújo, A., Scherpereel, A., Kopp, H., Bironzo, P., Massard, G., Jiménez, D., Falanga, A., et al. (2024) · Cancers · doi:10.3390/cancers16020450 · Cited by 12
“In RCTs comparing VKAs with DOACs, cancer patients were under-represented [133–138].”
BackgroundResultDix, C. H. K., Doyle, A. J., Breen, K. A., & Hunt, B. J. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2379-7288 · Cited by 8
Prise en charge de la maladie thromboembolique veineuse en 2015
Galanaud, J. ‐., Messas, E., Blanchet‐Deverly, A., Quéré, I., Wahl, D. G., & Pernod, G. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.06.004 · Cited by 8
Schmerge, M., Earl, S. R., & Kline, C. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000043 · Cited by 8
Ohmori, H., Kada, A., Nakamura, M., Saito, A. M., Sanayama, Y., Shinagawa, T., Fujita, H., Wakisaka, A., Maruhashi, K., Mizukami, A., et al. (2019) · Annals of Vascular Diseases · doi:10.3400/avd.oa.19-00040 · Cited by 8
Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists
Rossini, R., Quadri, G., Rognoni, A., Nardi, F., Varbella, F., & Musumeci, G. (2019) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.19.04985-5 · Cited by 8
Invasive and Pharmacological Treatment of Deep Vein Thrombosis: A Scoping Review
Sagris, Μ., Tzoumas, A., Kokkinidis, D. G., Korosoglou, G., Lichtenberg, M. K. W., & Tzavellas, G. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220418084339 · Cited by 10
New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
Wumaier, K., Li, W., & Cui, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s373726 · Cited by 10
Fan, G., Wang, D., Zhang, M., Luo, X., Zhai, Z., & Wu, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.979911 · Cited by 9
Darche, F. F., Fabricius, L. C., Helmschrott, M., Rahm, A., Ehlermann, P., Bruckner, T., Sommer, W., Warnecke, G., Frey, N., & Rivinius, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134334 · Cited by 8
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P. B., Wang, D., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-023-00576-2 · Cited by 9
“NOACs not only reduce the frequency of treatment monitoring compared with VKA, but also have similar efficacy in reducing the risk of VTE and a lower risk of overall bleeding (especially intracranial bleeding) in the general population [19].”
BackgroundDirect oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Khairani, C. D., Bejjani, A., Assi, A. A., Porio, N. D., Talasaz, A. H., Piazza, G., Cushman, M., & Bikdeli, B. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102424 · Cited by 10
Sueta, D., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Kaneda, K., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., et al. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2316-5269 · Cited by 8
The target-specific oral anticoagulants: practical considerations
Garcia, D. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.510 · Cited by 8
Upstream versus downstream thrombin inhibition
Gulpen, A. J. W., ten Cate‐Hoek, A. J., & Cate, H. T. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1224179 · Cited by 8
“HOKUSAI [8] Randomized, double blind, double dummy, noninferiority.”
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review
AlHajri, L., Jabbari, S., AlEmad, H., AlMahri, K., AlMahri, M., & AlKitbi, N. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416675732 · Cited by 8
Venous blood clot structure characterization using scattering operator
Berthomier, T., Mansour, A., Bressollette, L., Roy, F. L., & Mottier, D. (2016) · International Conference on Frontiers of Signal Processing (ICFSP) · doi:10.1109/icfsp.2016.7802960 · Cited by 10
New oral anti-coagulation drugs and prostate biopsy: a call for guidelines
Coscarella, M., Motte, S., Dalati, M.-F., Silva, T. O. E., Entezari, K., & Roumeguère, T. (2018) · Therapeutic Advances in Urology · doi:10.1177/1756287218811037 · Cited by 8
Direct oral anticoagulants and travel-related venous thromboembolism
Chamnanchanunt, S., & Rojnuckarin, P. (2018) · Open Medicine · doi:10.1515/med-2018-0085 · Cited by 8
“The results of any doses of apixaban were similar to the standard regimen (LMWH followed by VKA) in the incidences of VTE related complications (4.7% versus 4.2”
BackgroundMethodInfluentialIn vitro assessment of edoxaban anticoagulant effect in pediatric plasma
Sinegre, T., Zlobecki, M., Doré, É., Pereira, B., Grèze, V., & Lebreton, A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.04.014 · Cited by 8
Factors related to inappropriate edoxaban use
Jang, B. M., Lee, O. S., Shin, E. J., Cho, E. J., Suh, S. Y., Cho, Y. S., Lee, M. K., & Rhie, S. J. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12999 · Cited by 10
Tsai, C.-J., & Lee, C.-Y. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000206 · Cited by 7
“24-mo Villalta score, median (IQR) 6 (4-8) 3 (2-5) 0.”
BackgroundInfluentialPrescribing Pattern of Oral Anticoagulants in Patients With Obesity
Falk, K., McComb, M. N., Shapiro, N. L., & Uppuluri, E. M. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020969276 · Cited by 9
“The pivotal trials that led to guideline consensus recommending DOACs over VKAs for anticoagulation did not include a large number of obese patients.(6-14) The DOAC trials for VTE and AF reported a range from 12.”
BackgroundGhazvinian, R., Elf, J. L., Löfvendahl, S., Holst, J., & Gottsäter, A. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620937352 · Cited by 11
Kaneda, K., Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.022 · Cited by 11
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
Bavalia, R., Bistervels, I. M., Boersma, W. G., Quéré, I., Brisot, D., Falvo, N., Stéphan, D., Couturaud, F., Schellong, S., Beyer‐Westendorf, J., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12566 · Cited by 8
Apixaban Use in Patients with Protein C and S Deficiency: A Case Series and Review of Literature
Sulaiman, K. A. A., Alsuwayyid, F., Alrashidi, A., Alhijris, M., Almutairi, F., Alharthi, F., Esba, L. C. A., Aljuhani, O., & Badreldin, H. A. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s344083 · Cited by 8
Wang, M., Paterson, M., Thabane, L., Siegal, D. M., Mbuagbaw, L. C. E., Targownik, L. E., & Holbrook, A. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057991 · Cited by 9
Challenges in Cerebral Venous Thrombosis Management—Case Reports and Short Literature Review
Pleşa, C., Jijie, A., Toma, G. S., Ranetti, A.-E., Manole, A. M., Rotaru, R. M., Caloianu, I., Anghel, D. N., & Dulămea, A. O. (2023) · Life · doi:10.3390/life13020334 · Cited by 8
Age and long-term outcomes of patients with venous thromboembolism: From the COMMAND VTE Registry
Takahashi, K., Yamashita, Y., Morimoto, T., Tada, T., Sakamoto, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.04.050 · Cited by 8
Rueda-Camino, J. A., Barba, R., Otalora, S., Bura-Rivière, A., Visonà, A., Mahé, I., Alda‐Lozano, A., Megido, J. A., Pacheco-Gómez, N., Rosovsky, R. P. G., et al. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.12.001 · Cited by 8
Ferns, S. J., & Naccarelli, G. V. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.006 · Cited by 8
Johnston, S. (2015) · Dentistry Journal · doi:10.3390/dj3040102 · Cited by 8
“Following a number of clinical trials [25,26], another FXaI edoxaban (Savaysa [US] or Lixiana [EU]) produced by Daiichi Sankyo has recently been approved by the FDA, has been granted approval marketing authorisation in Europe and is currently being considered by NICE for use in the management of patients with AF and i…”
BackgroundInfluentialRisk assessment and management of high and intermediate risk pulmonary embolism
Meyer, G., Sanchez, O., & Jiménez, D. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.10.009 · Cited by 10
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Rosovsky, R. P. G., & Merli, G. J. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.003 · Cited by 8
Indran, T., Cummins, A., Bennett, A., Wood, E. M., Brown, S., McQuilten, Z., Tran, H. A., Epi, M., Chan, N., Chunilal, S. D., et al. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1676320 · Cited by 8
Nishimoto, Y., Yamashita, Y., Morimoto, T., Saga, S., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-1314 · Cited by 8
Wang, X., Wang, S., Morse, M. A., Jiang, N., Zhao, Y., Song, Y., Zhou, L., Huang, H., Zhou, X., Hobeika, A. C., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01844-7 · Cited by 8
Bando, T., Ueno, Y., Shimo, D., Kuroyama, T., Mikami, K., Hori, S., & Hirai, O. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105261 · Cited by 8
Sun, X., Ze, B., Zhang, L., BaiMa, Y.-Z., Zuo, W., Zhao, B., & GeSang, L.-B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07110-w · Cited by 8
Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on general measures
Fusco, S. A. D., Lucà, F., Benvenuto, M., Iorio, A., Fiscella, D., D’Ascenzo, F., Madeo, A., Colivicchi, F., Lenarda, A. D., & Gulizia, M. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.061 · Cited by 8
Huqi, A., Zoccali, C., Giugliano, R. P., & Caterina, R. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac450 · Cited by 8
Sueta, D., Kaikita, K., Okamoto, N., Yamabe, S., Ishii, M., Arima, Y., Ito, M., Oimatsu, Y., Mitsuse, T., Iwashita, S., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0612 · Cited by 9
Nielsen, A. H., Poulsen, P. B., Dybro, L., Kloster, B., Lorentzen, A., Olsen, J., & Kümler, T. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1668193 · Cited by 9
Tafur, A. J., Brenner, B., Rodríguez, P. D., Torrecillas, L. G., Pedrajas, J. M., Mazzolai, L., Montenegro, A. C., Tirado, R., Sánchez, A. V., Monréal, M., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2615-4591 · Cited by 10
“19 Although there have been small studies on Asian populations, 20 – 23 notably Japanese cohorts, the representation of other non-White groups in VTE research is minimal.”
Barrios, V., & Escobar, C. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1053871 · Cited by 8
Kommentar zur 2014-ESC-Leitlinie zum Management der akuten Lungenembolie
Konstantinides, S., Bauersachs, J. K., Mayer, E., & Hambrecht, R. (2015) · Der Kardiologe · doi:10.1007/s12181-015-0008-6 · Cited by 7
Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey
Wang, M., Chen, Z., Wong, M., Thabane, L., Mbuagbaw, L. C. E., Siegal, D. M., Gal, G. L., & Holbrook, A. M. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.02.016 · Cited by 8
Riva, N., & Ageno, W. (2015) · PubMed · doi:10.2450/2015.0057-15 · Cited by 9
Lavalle, C., Mariani, M. V., Piro, A., Magnocavallo, M., Vetta, G., Trivigno, S., Forleo, G. B., Rocca, D. G. D., Uguccioni, M., Russo, V., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113207 · Cited by 7
Imura, M., Yamamoto, T., & Hiasa, K. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00290-6 · Cited by 7
Becattini, C., Agnelli, G., Diamanti, M., Maggioni, A. P., Vanni, S., Dentali, F., Enea, I., Bortolotti, P., Vecchi, M. D., Artusi, N., et al. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107245 · Cited by 8
Living on Oral Anticoagulants: Duke Anticoagulation Satisfaction Scale Results
Mameli, A., Sestu, A., Marongiu, F., & Barcellona, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247574 · Cited by 7
“Moreover, both clinical trials and real-life studies have shown that DOACs safety is greater than that of coumarin derivatives [1–9].”
BackgroundDirect Oral Anticoagulants for Pulmonary Embolism
Pizzi, R., Cimini, L. A., Ageno, W., & Becattini, C. (2024) · Hämostaseologie · doi:10.1055/a-2105-8736 · Cited by 9
“5 – 8 In this review, we want to summarize the current and most important literature regarding the use of DOACs in PE patients, a therapeutic strategy that has rapidly changed the acute phase treatment and secondary prevention of this disease.”
BackgroundPessôa, R. L., Kessler, V. G., Becker, G. G., Garcia, G. M., Araldi, P. V. D., & Aver, P. V. (2024) · Vascular and Endovascular Surgery · doi:10.1177/15385744241253201 · Cited by 10
“24 It is questionable whether the result would be the same in a study carried out with a larger population of elderly people.”
Mehrpooya, M., Barakzehi, M. R., & Nikoobakhsh, M. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.04.019 · Cited by 10
Anticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
The role of novel anticoagulants in the management of venous thromboembolism
Skeik, N., Murphy, C. J., & Porten, B. R. (2014) · Vascular Medicine · doi:10.1177/1358863x14534309 · Cited by 7
Shao, J.-B., Cai-fang, N., Duan, P.-F., & Jin, Y.-H. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000438 · Cited by 9
Iba, T., Emmi, M., Hiki, M., Nagayama, M., Aihara, K., Tabe, Y., Yuri, M., & Ohsaka, A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1975-5 · Cited by 9
Clinical Implications of Reversal Agents for Direct Oral Anticoagulants
Monagle, S. R., Eikelboom, J. W., Ng, K. H., & Bhagirath, V. C. (2017) · Future Cardiology · doi:10.2217/fca-2016-0070 · Cited by 7
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Trends in Mortality of Acute Pulmonary Embolism
Ho, A. T. N., Bellamy, N., & Naydenov, S. K. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1725059 · Cited by 10
Nakano, Y., Adachi, S., Imai, R., Yoshida, M., Shimokata, S., Murohara, T., & Kondo, T. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1247 · Cited by 7
“History of major bleeding, n (%) 10 (8) 6 (7) 4 (9) 0.”
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients
Langella, V., Bottino, R., Asti, A., Maresca, G., Palma, G. D., Pomponi, D., Sassone, C., Imbalzano, E., & Russo, V. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1964359 · Cited by 7
“after a minimum of 5 days of parenteral anticoagulation, therefore PE treatment with edoxaban was slightly influenced in outcomes by the in-hospital protocol of initiating therapy with LMWH or fondaparinux in COVID-19 patients with PE [8,31].”
BackgroundAloysius, M. M., Perisetti, A., Goyal, H., Boregowda, U., Jecmenica, M., Cheryala, M., Bajaj, A., Milekic, B., Babic, M., Bansal, P., et al. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0658 · Cited by 14
“Indications were atrial fibrillation (n=9), VTE (n=2), pulmonary embolism (PE) (n=1), VTE/PE (n=1), mechanical valve thromboprophylaxis (n=1).”
BackgroundInfluentialProphylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer
Meng, X., Ahmed, M., Courtney, K. D., Arafat, W., Ibrahim, I., Margulis, V., Nichols, C. R., & Bagrodia, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724682 · Cited by 7
Ayalon‐Dangur, I., Vega, Y., Israel, M. R., Grossman, A., Spectre, G., Shochat, T., Leibovici, L., & Gafter‐Gvili, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235673 · Cited by 7
DOAC drug interactions management resource
Chadha, A., Guirguis, M. S., & Bungard, T. J. (2022) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635221116100 · Cited by 8
“Unique to edoxaban are recommendations for dose reduction (from 60 to 30 mg daily) in the presence of P-gp inhibitors (except amiodarone and verapamil), with certain drugs listed based on clinical trial protocols or product monograph content.(5,10) As the front-line clinician continues to manage more complex clinical…”
BackgroundChan, Y., Chao, T., Chen, S., Lee, H., Chen, W.-M., Li, P., Yeh, Y., Kuo, C.-T., See, L., & Lip, G. Y. H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.43307 · Cited by 8
Liu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
“2022, 9, x FOR PEER REVIEW 5 of 14 Hokusai-VTE, 2013 [20] Edoxaban 3633 1.00 66 11 132 51 Warfarin-S 3594 67 24 124 43 PADIS-PE, 2017 [6] Warfarin-S 184 1.50 28 6 None 13 Placebo 187 39 5 None 6 EINSTEIN CHOICE, 2017 [15] Rivaroxaban-L 1127 1.00 13 5 22 2 Rivaroxaban-S 1107 17 6 30 8 Asprin 1131 59 3 20 7 PADIS-DVT, 2…”
BackgroundInfluentialSpeed, V., Czuprynska, J., Patel, J. P., & Arya, R. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.102240 · Cited by 7
Escobar, C., Palacios, B., Villarreal, M., Gutiérrez, M., Capel, M., Hernández, I., García-Gil, M., Bryant, L. L., & Arenillas, J. F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061677 · Cited by 7
Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants
Cohen, A. T., Sinnadurai, J., Kim, J. Y., Park, K. H., Sompradeekul, S., Tambunan, K. L., Tran, H. A., Tsai, I., Wård, C., & Wong, R. S. M. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.05.024 · Cited by 8
“Prespecified subgroup analyses of patients with PE with or without DVT (shown in supplementary appendices) in RE-COVER I & II [100], AMPLIFY [103] and Hokusai-VTE [104] all showed no significant interactions compared with their overall efficacy and safety results.”
BackgroundMethodResultInfluentialSYSTEMATIC REVIEW AND META-ANALYSIS: PITFALLS OF METHODS
Lukina, Y. V., Martsevich, S. Y., & Кутишенко, Н. П. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-2-180-185 · Cited by 11
Prise en charge de l’embolie pulmonaire en 2015
Galanaud, J. ‐., Blanchet‐Deverly, A., Pernod, G., & Quéré, I. (2015) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2015.07.003 · Cited by 7
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism
Bauersachs, R. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.022 · Cited by 7
Connell, N. T., & Butera, J. N. (2015) · PubMed · Cited by 9
An update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
“The direct factor Xa inhibitor edoxaban tosylate was tested for treatment of VTE (Table 3) in a randomized, double-blind, noninferiority study evaluating the efficacy and safety of edoxaban given 60 mg once daily versus standard heparin/warfarin treatment in patients with symptomatic DVT or PE for 3– 12 months – HOKUS…”
MethodThe Treatment of Venous Thromboembolism in Patients with Cancer
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_111 · Cited by 7
Enea, I., Roncon, L., Gulizia, M. M., Azzarito, M., Becattini, C., Bongarzoni, A., Casazza, F., Cuccia, C., D’Agostino, C., Rugolotto, M., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux026 · Cited by 7
“However, the inclusion criteria showed some differences among trials.(3,7,10,52) Regarding chronic RF, due to the different pharmacokinetics of the molecules, that have a specific elimination, an increased incidence of VTE events and bleeding complications during anticoagulant therapy has been documented.”
BackgroundIn silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
Pu, Y., Liu, H., Zhou, Y., Peng, J., Li, Y., Li, P., Li, Y., Liu, X., & Zhang, L. (2017) · Natural Products and Bioprospecting · doi:10.1007/s13659-017-0126-x · Cited by 7
Santos, S. M., Cunha, S., Baptista, R., Monteiro, S. R., Monteiro, P. F., Gonçalves, F., & Pêgo, M. (2017) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.01.010 · Cited by 7
MORISHIMA, Y., & Honda, Y. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1673-7 · Cited by 7
van der Pol, L. M., Mairuhu, A. T. A., Leroyer, C., Couturaud, F., Huisman, M., Klok, F. A., & Tromeur, C. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642622 · Cited by 10
Extended anticoagulation for unprovoked venous thromboembolism
Castellucci, L. A., de Wit, K., Garcia, D. A., Ortel, T. L., & Gal, G. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12121 · Cited by 7
Riva, L., Ageno, W., Pasquale, G. D., Agnelli, G., & Rubboli, A. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.07.133 · Cited by 7
Moyer, G. C., Bannow, B. S., Thornburg, C. D., Rosovsky, R. P. G., Wang, T., Woller, S. C., Thornhill, D., & Kreuziger, L. B. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618804080 · Cited by 7
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.